Metagenomi Therapeutics, Inc.

For the period ended Sep 30, 2026. Filed Nov 10, 2026.

About this filing

A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.

Sep 30, 2026 · Filed Nov 10, 2026

MGX$0.70-3.0%Stored close · as of Nov 10, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Contents

Condensed Statements of Operations and Comprehensive Loss

(In thousands, except share and per share data)

	Three Months EndedSeptember 30,		Nine Months EndedSeptember 30,
	2026	2025	2026	2025
Collaboration revenue	$2,184	$8,659	$3,175	$21,299
Operating expenses:
Research and development	17,532	25,283	59,344	72,932
General and administrative	6,878	6,215	19,417	20,013
Total operating expenses	24,410	31,498	78,761	92,945
Loss from operations	(22,226)	(22,839)	(75,586)	(71,646)
Other income (expense):
Interest income	1,047	2,214	3,842	7,586
Change in fair value of long-term investments	—	—	—	(1,292)
Other income (expense), net	53	(2)	87	(80)
Total other income (expense), net	1,100	2,212	3,929	6,214
Net loss before provision for income taxes	(21,126)	(20,627)	(71,657)	(65,432)
Benefit from (provision for) income taxes	—	234	(10)	92
Net loss	$(21,126)	$(20,393)	$(71,667)	$(65,340)
Other comprehensive income (loss):
Unrealized loss on available-for-sale marketable securities	(37)	(1)	(419)	(338)
Comprehensive loss	$(21,163)	$(20,394)	$(72,086)	$(65,678)
Net loss per share attributable to common stockholders, basic and diluted	$(0.56)	$(0.55)	$(1.90)	$(1.76)
Weighted average common shares outstanding, basic and diluted	37,775,051	37,349,449	37,672,176	37,176,361

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.